cbdc full form Featured snippets

The action plan proposes that by 2027, we will strive to land a number of representative M&A cases in key industries, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan; Gather 3-5 professional M&A fund managers with strong industry influence, and the M&A service ability of intermediaries has been greatly improved, and the M&A service platform has played an active role; The joint efforts of the city, urban areas, government and enterprises have been significantly strengthened, and the policy guarantee system has made concerted efforts to build Shanghai into a pioneering area and demonstration area for mergers and acquisitions of listed companies with significantly improved industrial level, more sound M&A ecology and diversified and long-term cooperation mechanism, so as to better serve the high-quality development of the economy.Shanghai state-owned companies are expected to directly benefit from the action plan. According to the statistics of Securities Times and Data Treasure, there are 37 A-shares owned by Shanghai State-owned Assets with a market value of less than 10 billion yuan. Among them, the market value of Kaikai Industrial, Chuangchuang International, First Pharmaceutical and other stocks is less than 3 billion yuan, and the market value of Yatong, Changjiang Investment, Changlian, Shanghai Jiubai and *ST Tianwo is less than 4 billion yuan.Shanghai state-owned companies are expected to directly benefit from the action plan. According to the statistics of Securities Times and Data Treasure, there are 37 A-shares owned by Shanghai State-owned Assets with a market value of less than 10 billion yuan. Among them, the market value of Kaikai Industrial, Chuangchuang International, First Pharmaceutical and other stocks is less than 3 billion yuan, and the market value of Yatong, Changjiang Investment, Changlian, Shanghai Jiubai and *ST Tianwo is less than 4 billion yuan.

The action plan proposes that by 2027, we will strive to land a number of representative M&A cases in key industries, and cultivate about 10 internationally competitive listed companies in key industries such as integrated circuits, biomedicine and new materials, forming a scale of M&A transactions of 300 billion yuan and activating total assets of over 2 trillion yuan; Gather 3-5 professional M&A fund managers with strong industry influence, and the M&A service ability of intermediaries has been greatly improved, and the M&A service platform has played an active role; The joint efforts of the city, urban areas, government and enterprises have been significantly strengthened, and the policy guarantee system has made concerted efforts to build Shanghai into a pioneering area and demonstration area for mergers and acquisitions of listed companies with significantly improved industrial level, more sound M&A ecology and diversified and long-term cooperation mechanism, so as to better serve the high-quality development of the economy.The benefits are endless.Shanghai state-owned companies are expected to directly benefit from the action plan. According to the statistics of Securities Times and Data Treasure, there are 37 A-shares owned by Shanghai State-owned Assets with a market value of less than 10 billion yuan. Among them, the market value of Kaikai Industrial, Chuangchuang International, First Pharmaceutical and other stocks is less than 3 billion yuan, and the market value of Yatong, Changjiang Investment, Changlian, Shanghai Jiubai and *ST Tianwo is less than 4 billion yuan.

According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.Shanghai local hard technology stocks exposed.The stagflation stocks mainly include Haohaishengke, Shanghai Laishi and Weir. Among them, Haohai Shengke increased by less than 10%. The company is a scientific and technological innovative enterprise that applies biomedical materials technology and genetic engineering technology to research, develop, produce and sell medical devices and drugs. It is committed to providing innovative medical products for the market through technological innovation and transformation, integration of domestic and foreign resources and large-scale production, and gradually realizing the import substitution of related medical products, thus becoming a leading enterprise in the field of biomedical materials.